In contrast, BEVs administration in two mouse models for arthritis reduced serum levels of MCP-1 and IL-6 correlated with delays in the onset of arthritis and diminished cartilage pathology and bone marrow inflammation51. The gene discussed is CCL2; the disease is arthritic joint disease.